Form 13-F position report

BLUEPRINT MEDICINES CORP

Reported by ALLIANCEBERNSTEIN L P

BPMC CUSIP 09627Y109 Manager CIK 0001109448

Reported 765,387 shares, down 430,853 (36.0%) from the prior quarter.

Reported value -7.3%; share count -36.0% vs. the prior quarter.

Reduced
% of reported 13F value 0.03% This manager · Q2 2025
Shares 765,387 Quarter-end amount reported
Reported value $98,107,306 Fair value at quarter end
Consecutive quarters held 41 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 160745000
2022-03-31 96522000
2022-06-30 75634000
2022-09-30 92846000
2022-12-31 67298951
2023-03-31 78363762
2023-06-30 101826639
2023-09-30 75192096
2023-12-31 125260352
2024-03-31 114172737
2024-06-30 122761636
2024-09-30 112637713
2024-12-31 99258279
2025-03-31 105879202
2025-06-30 98107306
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for BLUEPRINT MEDICINES CORP held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -765,387 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 765,387 -430,853 (-36.0%) 0.03% $98,107,306 2025-08-14
Q1 2025 Added 1,196,240 +58,218 (5.1%) 0.04% $105,879,202 2025-05-15
Q4 2024 Reduced 1,138,022 -79,683 (-6.5%) 0.03% $99,258,279 2025-02-12
Q3 2024 Added 1,217,705 +78,703 (6.9%) 0.04% $112,637,713 2024-11-14
Q2 2024 Reduced 1,139,002 -64,590 (-5.4%) 0.04% $122,761,636 2024-08-14
Q1 2024 Reduced 1,203,592 -154,391 (-11.4%) 0.04% $114,172,737 2024-05-14
Q4 2023 Reduced 1,357,983 -139,271 (-9.3%) 0.05% $125,260,352 2024-02-14
Q3 2023 Reduced 1,497,254 -113,927 (-7.1%) 0.03% $75,192,096 2023-11-14
Q2 2023 Reduced 1,611,181 -130,623 (-7.5%) 0.04% $101,826,639 2023-08-15
Q1 2023 Added 1,741,804 +205,649 (13.4%) 0.03% $78,363,762 2023-05-15
Q4 2022 Added 1,536,155 +127,048 (9.0%) 0.03% $67,298,951 2023-02-15
Q3 2022 Reduced 1,409,107 -88,298 (-5.9%) 0.04% $92,846,000 2022-11-15
Q2 2022 Reduced 1,497,405 -13,586 (-0.9%) 0.03% $75,634,000 2022-08-15
Q1 2022 Added 1,510,991 +10,246 (0.7%) 0.04% $96,522,000 2022-05-13
Q4 2021 Added 1,500,745 +106,541 (7.6%) 0.06% $160,745,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

465 managers reported BLUEPRINT MEDICINES CORP for Q2 2025.

Managers reporting BLUEPRINT MEDICINES CORP in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Reduced 6,416,603 -223,920 0.01% $822,480,172 41 qtrs
BlackRock Inc Reduced 6,118,428 -592,280 0.01% $784,260,102 4 qtrs
Pentwater Capital Management LP New 3,900,000 +3,900,000 3.24% $499,902,000 1 qtr
HBK INVESTMENTS L P New 3,200,924 +3,200,924 5.35% $410,294,438 1 qtr
STATE STREET CORPORATION Reduced 2,230,980 -453,137 0.01% $285,967,016 41 qtrs
UBS Group AG Added 2,167,028 +1,953,223 0.05% $277,769,649 41 qtrs
FIL Ltd New 1,759,500 +1,759,500 0.19% $225,532,710 1 qtr
UBS OCONNOR LLC Added 1,713,587 +1,698,722 5.96% $219,647,582 14 qtrs
Barclays PLC Added 1,556,918 +1,427,323 0.05% $199,565,749 41 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,541,013 +18,366 0.01% $197,551,465 40 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
680,484
Shared
0
None
84,903

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.